BIOTIME TO PRESENT SCiSTAR CLINICAL STUDY TOP-LINE DATA AT THE 26

TO PRESENT SCiSTAR CLINICAL STUDY TOP-LINE DATA AT THE 26TH ANNUAL AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR CONFERENCE

CA - April 26, 2019 - BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology

company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime,

will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on

April 26th, 2019 at 10:30am EDT part of Session 6: "Spinal Cord Injury". Dr. Wirth's presentation

is entitled "Top-line 12-month Results from the SCiStar Study - A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived

Oligodendrocyte Progenitor Cells (OPC1) in Patients with Subacute Cervical Spinal Cord Injury". ASNTR will be held April

25 - 27, 2019 at the Sheraton Sand Key Resort in Clearwater Beach, Florida.

believe the primary goals of the SCiStar Study, which were to observe the safety of OPC1 in cervical spinal cord injury patients

as well as other important metrics including related to the optimal timing of OPC1 injection, tolerability of the immunosuppression

regimen, engraftment of OPC1 cells, and rates of motor recovery observed among different study subpopulations, have all been successfully

achieved," stated Dr. Wirth. "We now

are in the process of analyzing the full data set from the SCiStar Study to inform how best to proceed with this promising program.

We expect to propose a clinical plan to the U.S. Food and Drug Administration later this year and expect to share the outcome

of those discussions when they are available."

appreciate the support of the California Institute for Regenerative Medicine, the

world's largest institution dedicated to bringing the future of cellular medicine closer to reality, whose generous grant

funding to date of $14.3 million has helped advance the clinical development of our OPC1 program and generate these encouraging

clinical results in patients with traumatic spinal cord injuries," stated Brian M. Culley, Chief Executive Officer of BioTime.

"We look forward to continuing our partnership with CIRM and will support their mission to accelerate stem cell treatments

to patients with unmet medical needs and fast-track the development of the most promising stem cell technologies."

SCiStar Study is an open-label, single-arm trial testing three sequential escalating doses of OPC1 administered 21 to 42

days post-injury, at up to 20 million OPC1 cells in 25 subjects with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to

C-7) acute spinal cord injuries (SCI). These individuals have essentially lost all movement below their injury site and experience

severe paralysis of the upper and lower limbs. AIS-A subjects have lost all motor and sensory function below their injury site,

while AIS-B subjects have lost all motor function but may have retained some minimal sensory function below their injury site.

The primary endpoint in the SCiStar study was safety as assessed by the frequency and severity

of adverse events related to OPC1, the injection procedure, and immunosuppression with short-term, low-dose tacrolimus. Secondary

outcome measures included neurological functions as measured by upper extremity motor scores and motor level on International

Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examinations at 30, 60, 90, 180, 270, and 365 days after

are a summary of key findings from the SCiStar Study. A copy of Dr. Wirth's presentation will be available on the Events

section of BioTime's website concurrent with his presentation at ASNTR.

is an oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial known as SCiStar for

the treatment of acute spinal cord injuries. OPCs are naturally-occurring precursors to the cells which provide electrical insulation

for nerve axons in the form of a myelin sheath. SCI occurs when the spinal cord is subjected to a severe crush or contusion injury

and typically results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder

control and other body functions. The clinical development of the OPC1 program has been

partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine. OPC1 has received Regenerative

Medicine Advanced Therapy (RMAT) designation for the treatment of acute SCI and has been granted Orphan Drug designation from

the U.S. Food and Drug Administration (FDA).

is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions

associated with demyelination, and aiding the body in detecting and combating cancer. BioTime's programs are based on its

proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform BioTime

develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting

materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to

degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to

cancer. BioTime's clinical assets include (i) OpRegen , a retinal pigment epithelium transplant therapy in

Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed

world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord

injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development

for the treatment of non-small cell lung cancer. For more information, please visit www.biotimeinc.com.

cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking

statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may,"

"will," "estimate," "continue," "anticipate," "design," "intend,"

"expect," "could," "plan," "potential," "predict," "seek,"

"should," "would," "contemplate," project," "target," "tend to,"

or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating

to the timing of when we propose a clinical plan to the U.S. Food and Drug Administration and the sharing of the outcome of those

discussions when they are available, and that MRI results are supportive evidence showing that OPC1 cells have durably engrafted

to help prevent cavitation at the injury site. Forward-looking statements involve known and unknown risks, uncertainties and other

factors that may cause BioTime's actual results, performance or achievements to be materially different from future results,

performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation,

risk and uncertainties related to: BioTime's ability to raise additional capital when and as needed, to advance its product

candidates; BioTime's ability to develop and commercialize product candidates; the failure or delay in starting, conducting

and completing clinical trials or obtaining FDA or foreign regulatory approval for BioTime's product candidates in a timely

manner; the therapeutic potential of BioTime's product candidates, and the disease indications for which BioTime intends

to develop its product candidates; BioTime's ability to conduct and design successful clinical trials, to enroll a sufficient

number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to

demonstrate sufficient efficacy of its product candidates; developments by BioTime competitors that make BioTime's product

candidates less competitive or obsolete; BioTime's ability to manufacture its product candidates for clinical development

and, if approved, for commercialization, and the timing and costs of such manufacture; the performance of third parties in connection

with the development and manufacture of BioTime's product candidates, including third parties conducting clinical trials

as well as third-party suppliers and manufacturers; the potential of BioTime's cell therapy platform, and BioTime's

plans to apply its platform to research, develop and commercialize our product candidates; BioTime's ability, and the ability

of its licensors, to obtain, maintain, defend and enforce intellectual property rights protecting BioTime's product candidates,

and BioTime's ability to develop and commercialize its product candidates without infringing the proprietary rights of third

parties; BioTime's ability to recruit and retain key personnel; and BioTime's ability to successfully integrate the

operations of Asterias into BioTime. BioTime's forward-looking statements are based upon its current expectations and involve

assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in

their entirety by these cautionary statements. For a detailed description of BioTime's risks and uncertainties, you are

encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are

cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made.

BioTime undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the

date on which they were made, except as required by law.

(Gogawa@troutgroup.com)